Other formats:
BibTeX
LaTeX
RIS
@article{1726859,
author = {Vochyanova, Z and Čulenová, Marie and Rotrekl, Dominik and Smekal, V and Fictum, P and Suchý, Pavel and Gajdziok, Jan and Šmejkal, Karel and Hosek, J},
article_location = {San Francisco},
article_number = {8},
doi = {http://dx.doi.org/10.1371/journal.pone.0182464},
language = {eng},
issn = {1932-6203},
journal = {Plos one},
title = {Prenylated flavonoid morusin protects against TNBS-induced colitis in rats},
volume = {12},
year = {2017}
}
TY - JOUR
ID - 1726859
AU - Vochyanova, Z - Čulenová, Marie - Rotrekl, Dominik - Smekal, V - Fictum, P - Suchý, Pavel - Gajdziok, Jan - Šmejkal, Karel - Hosek, J
PY - 2017
TI - Prenylated flavonoid morusin protects against TNBS-induced colitis in rats
JF - Plos one
VL - 12
IS - 8
PB - Public Library of Science
SN - 19326203
N2 - Morusin is a prenylated flavonoid isolated from the root bark of Morus alba. Many studies have shown the ability of flavonoids to act as anti-inflammatory agents. The aim of this study was to evaluate the effect of morusin on experimentally colitis induced by 2,4,6-trinitroben-zensulfonic acid in Wistar rats and to compare it with sulfasalazine, a drug conventionally used in the treatment of inflammatory bowel disease. Morusin was administered by gavage at doses of 12.5, 25, or 50 mg/kg/day for five days. The colonic tissue was evaluated macroscopically, histologically, and by performing immunodetection and zymographic analysis to determine the levels of antioxidant enzymes [superoxide dismutase (SOD) and catalase (CAT)], interleukin (IL)-1 beta, and transforming growth factor (TGF)-beta 1 and the activities of matrix metalloproteinases (MMP) 2 and 9. The tissue damage scores were significantly reduced with increasing dose of morusin, however efficacy was not demonstrated at the highest dose. At the dose of 12.5 mg/kg, morusin exerted therapeutic effectivity similar to that of sulfasalazine (50 mg/kg). This was associated with significant reduction of TGF-beta 1 levels and MMP2 and MMP9 activities, and slight reduction of IL-1 beta. Our results suggest that morusin possesses therapeutic potential for the treatment of chronic inflammatory diseases.
ER -
VOCHYANOVA, Z, Marie ČULENOVÁ, Dominik ROTREKL, V SMEKAL, P FICTUM, Pavel SUCHÝ, Jan GAJDZIOK, Karel ŠMEJKAL and J HOSEK. Prenylated flavonoid morusin protects against TNBS-induced colitis in rats. \textit{Plos one}. San Francisco: Public Library of Science, 2017, vol.~12, No~8, 14 pp. ISSN~1932-6203. Available from: https://dx.doi.org/10.1371/journal.pone.0182464.
|
